Skip to content
value.today

Xeris Pharmaceuticals Inc.

Total raised
$84 M
4 rounds on record
Latest round
$30 M
May 2017
First round on record
Jul 2011
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Xeris Pharmaceuticals Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2017$30 MNo. 4$10 to $50 million

Xeris Pharmaceuticals Inc.: Raise no. 4, May 2017

Investors in this round

22 investors had bought by the notice of May 22, 2017: 22 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Xeris Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$30 M of $45 M offered; $15 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Brad Huckabee · Executive Officer
  • John Shannon · Executive Officer
  • Paul Edick · Executive Officer, Director
  • Cary McNair · Director
  • Jonathan Rigby · Director
  • Navneet Puri · Director
  • Robert Faulker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series C Preferred Stock”

Signed by Brad Huckabee, Secretary. Source: SEC Form D, newest notice filed May 22, 2017. Read the notice at the SEC.

equitySEC
Dec 2015$45 MNo. 3$10 to $50 million

Xeris Pharmaceuticals Inc.: Raise no. 3, Dec 2015

Investors in this round

48 investors had bought by the notice of Dec 30, 2016: 48 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Xeris Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$45 M of $50 M offered; $5 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Baum · Executive Officer, Director
  • Poul Strange · Executive Officer
  • Steven Prestrelski · Executive Officer
  • Cary McNair · Director
  • Jonathan Rigby · Director
  • Navneet Puri · Director
  • Robert Faulker · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series C Preferred Stock”

Signed by Douglas Baum, President & Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Dec 30, 2016. Read the notice at the SEC.

equitySEC
Sep 2014$7 MNo. 2$2 to $10 million

Xeris Pharmaceuticals Inc.: Raise no. 2, Sep 2014

Investors in this round

56 investors had bought by the notice of Sep 29, 2014: 56 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Xeris Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$7 M of $15 M offered; $8 M still to sell
Smallest investment taken
$25,000
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
$55,500
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Douglas Baum · Executive Officer, Director
  • John Kinzell · Executive Officer, Director
  • Steven Prestrelski · Executive Officer
  • Yash Sabharwal · Executive Officer
  • Shane Brisbin · Director
  • Timothy Sullivan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series B Preferred Stock”

Signed by Yash Sabharwal, Chief Operating Officer. Source: SEC Form D, newest notice filed Sep 29, 2014. Read the notice at the SEC.

equitySEC
Jul 2011$2 MNo. 1Under $2 million

Xeris Pharmaceuticals Inc.: Raise no. 1, Jul 2011

Investors in this round

19 investors had bought by the notice of Oct 12, 2011: 19 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 13 investors are named for Xeris Pharmaceuticals Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$2 M of $2 M offered; $0 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • John Kinzel · Executive Officer, Director
  • Steven Prestrelski · Executive Officer, Director
  • Yash Sabharwal · Executive Officer
  • Doug Baum · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Series A Preferred Stock Financing and Issuance of Series A Preferred Stock Warrants exercisable at $1.02 per share.”

Signed by John Kinzell, Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 12, 2011. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Xeris Pharmaceuticals Inc. chose not to state its revenue in its newest notice of a funding round (May 2017).

    SEC Form D · May 2017

  • The industry group it chose in its notices: Other.

    SEC Form D · May 2017

That is all the official record says: Xeris Pharmaceuticals Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

13 named in official filings. Open an investor to see everything it has backed.

Investors in Xeris Pharmaceuticals Inc.
InvestorKindAmountRoundRoleSource
Barry M. DeutschPersonnot statednot statedHeld Series C preferred stock (Form 3, 2018)SEC Form 3
Deerfield Management Company, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Mgmt III, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Mgmt L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Private Design Fund III, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Deerfield Special Situations Fund, L.P.Fund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
John Patrick Shannon Jr.Personnot statednot statedHeld Series C preferred stock (Form 3, 2018)SEC Form 3
Kenneth Erland JohnsonPersonnot statednot statedHeld Series C preferred stock (Form 3, 2018)SEC Form 3
Palmetto Partners 2014, LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Palmetto Partners 2015, LPFund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Palmetto Partners, Ltd.Fund or asset managernot statednot statedHeld Series B and C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Redmile Group, LLCFund or asset managernot statednot statedHeld Series C preferred stock, 10% owner (Form 3, 2018)SEC Form 3
Steven PrestrelskiPersonnot statednot statedHeld Series A and B preferred stock (Form 3, 2018)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 56 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Xeris Pharmaceuticals Inc.
NameRoleNamed in
Brad HuckabeeExecutive officerMay 2017
John ShannonExecutive officerMay 2017
Paul EdickExecutive officerMay 2017
Douglas BaumExecutive officerDec 2016
Poul StrangeExecutive officerDec 2016
Steven PrestrelskiExecutive officerDec 2016
Phillip JohnsonExecutive officerJan 2016
Yash SabharwalExecutive officerJan 2016
John KinzellExecutive officerSep 2014
John KinzelExecutive officerOct 2011
Mark SalimanExecutive officerJul 2011
Cary McNairDirectorMay 2017
Jonathan RigbyDirectorMay 2017
Navneet PuriDirectorMay 2017
Paul EdickDirectorMay 2017
Robert FaulkerDirectorMay 2017
Douglas BaumDirectorDec 2016
John KinzellDirectorSep 2014
Shane BrisbinDirectorSep 2014
Timothy SullivanDirectorSep 2014
Doug BaumDirectorOct 2011
John KinzelDirectorOct 2011
Steven PrestrelskiDirectorOct 2011